Pyrantel 250 mg (3 tablets)

The instruction for medical use of medicine Pyrantelum the Trade name Pyrantelum the International unlicensed name Pyrantelum Dosage Form of the Tablet, 250 mg Structure One tablet contains active agent - Pyrantelum of the embonat of 720 mg (it is equivalent to Pyrantelum of 250 mg), excipients: potato starch, povidone, silicon dioxide colloidal, ethyl cellulose, magnesium stearate, orange aroma. The description of the Tablet round, flat from both parties, with dividing risky, sand-yellow color with a gray-greenish shade with imperceptible specks with an orange flavor and a smell. Tablets darken under the influence of light, changing color in yellowy-brown. Pharmacotherapeutic group Anthelminthic drugs. Tetragidropirimidina derivatives. Pyrantelum. The ATX P02C C01 code the Pharmacological Pharmacokinetics Absorption Poorly properties is absorbed in digestive tract. Concentration of drug in plasma after reception of a single dose of 10 mg/kg of body weight makes 0.05 - 0.13 mkg/ml within from 1 to 3 hours. Distribution Data on penetration of drug through a placenta and in maternal milk and also about arrangement of drug in biological fabrics and liquids are absent (theoretically absorption of drug is minimum). Metabolism the Minimum quantity of the drug absorbed in digestive tract partially is metabolized in a liver up to N-methyl-1.3-propandiamina (0.8-5.6%). Removal from an organism More than 50% of the dose of drug accepted orally is removed in not changed view with excrements and less than 15% with urine in not changed look or in the form of a metabolite N-methyl-1.3-propandiamina. The pharmacodynamics Pyrantelum is effective drug in infection intestinal round worms. Affects muscles of intestinal nematodes, by depolarization of their neuromuscular connection and blockade of effect of cholinesterase. Immovable parasites are brought from intestines thanks to peristaltic movements. Does not cause migration of helminths, does not possess irritant action. Affects mature forms and on parasites in an early stage of development and does not affect larvae during their migration in fabrics. Drug is used first of all in infections with pinworms (Enterobius vermicularis) and ascarids (Ascaris lumbricoides). It can be applied in infection with a hookworm, has more effective effect at treatment of an ankilostomidoz, than at treatment of a necatoriasis. Indications - an enterobiosis - an ascaridosis - a dochmiasis - a necatoriasis the Route of administration and doses take the Drug inside, in time or after a meal, washing down with water. Before ingestion the tablet should be chewed or crushed carefully. In the diseases caused by Ascaris lumbricoides, Enterobius vermicularis, Ancylostoma duodenale and Necator americanus depending on age and the body weight of the patient the following doses are recommended: The age of the patient of a tablet of 250 mg of mg from 6 to 12 years 2,500 is more senior than 12 years and adults whose body weight does not exceed 75 kg 3,750 adults with body weight more than 75 kg 4 1000 In an ascaridosis and an enterobiosis (and also at a combination of these diseases) appoint the general medical dose (10 mg/kg/days) once. At an ankilostomidoza the daily dose (10 mg/kg/days) is accepted within 3 days once a day. At severe forms of a necatoriasis (massive invasions of Necator americanus) appoint 20 mg/kg/days within 2 days or 10 mg/kg/days within 3 days once a day. Side effects take place Side effects after the treatment termination. Seldom (≥1/10,000 to & lt, 1/1,000) - nausea, vomiting, pains and spasms of a stomach, lack of appetite, diarrhea, passing increase in activity of aminotransferases - a headache, dizziness, drowsiness, insomnia, weakness - skin rash With an unknown frequency - desires on defecation - hallucinations, confusion of consciousness, paresthesia, hearing disorders - Contraindication fever - hypersensitivity - simultaneous use of piperazin - a myasthenia (treatment period) Medicinal interactions not to apply to Pyrantelum or excipients along with piperazin. Combined use has antagonistic effect. Pyrantelum can increase concentration of theophylline in plasma. The special instructions Pyrantelum should be applied carefully – special medical control is necessary for patients: · with a liver failure as in the course of treatment drug can increase concentration AspAT, · with malnutrition or anemia. Attention 1. In an enterobiosis it is necessary to carry out simultaneous treatment of all in common living persons. 2. It is necessary to follow the rules of hygiene strictly. 3. After completion of the Pyrantelum drug treatment, in 14 days from the moment of reception, it is necessary to conduct control parasitological researches. Pregnancy and the period of a lactation of Controlled researches of safety of use of Pyrantelum at pregnancy it was not carried out therefore use of drug during this period is possible only as a last resort when the expected advantage for mother exceeds potential risk for a fruit. It is not recommended to appoint to women in the period of a lactation. If treatment by Pyrantelum is extremely necessary, feeding by a breast should be stopped. Features of influence on ability to driving or potentially dangerous mechanisms dizziness In some cases can be observed, in this regard it is necessary to be careful during driving of vehicles and service of the mechanical equipment. Overdose Symptoms: disorders of vision, a disorientation, dizziness, an unconscious state or dizziness when rising from a prone position or sitting, the increased perspiration, earlier not observed feeling of fatigue or weakness, irregular pulse, spasms, trembling and weakness of muscles, feeling of exhaustion, asphyxia (suffocation, a loss of consciousness). Treatment: symptomatic and supporting (early gastric lavage, support of passability of airways and breath, support of blood pressure). Specific antidote is absent. A form of release and packing On 3 tablets in planimetric bezjyacheykovy packing from aluminum foil. On 1 packing together with the instruction for use in the state and Russian languages place in a pack from cardboard. To Store storage conditions in the dry, protected from light place, at a temperature not above 25 °C. To store out of children's reach! A period of storage of 5 years not to use drug after expiry date Prescription status According to the prescription the Name and the country of the organization - producer the Pharmaceutical plant JSC Polpharm of st. of Pelplinsk 19, 83-200 Starogard Gdanski, Poland the Owner of the registration certificate of JSC Khimpharm, the Republic of Kazakhstan the Name and the country of the organization packer the Pharmaceutical plant JSC Polpharm, Poland the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) of JSC Khimpharm, Shymkent, Republic of Kazakhstan, Rashidov St., 81 Phone number 7252 (561342) Fax number 7252 (561342) the E-mail address of infomed@santo.kz